Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) will present at the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 5:40 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) will present at the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 5:40 PM ET. Key executives, including Chief Medical Officer Camille Bedrosian and Chief Financial Officer Mardi Dier, will lead the presentation. Interested parties can access the live and archived webcast on the company's website for 90 days following the event. Ultragenyx is dedicated to developing innovative therapies for rare and ultra-rare genetic diseases, with a focus on addressing high unmet medical needs.
Details
News Market Reaction – RARE
The recorded move for RARE in the trading session of this news was -0.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NOVATO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Camille Bedrosian, M.D., the company’s Chief Medical Officer, and Mardi Dier, the company’s Chief Financial Officer, will present at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022 at 5:40 PM ET.
The live and archived webcast of the presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contacts
Ultragenyx Pharmaceutical, Inc.
Investors
Rob Anstey
ir@ultragenyx.com
Media
Jeff Blake
415-612-7784
media@ultragenyx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.